Precigen Story

<div class='circular--portrait' style='background:#000000;color: #f2f2f2;font-size:4em;'>PR</div>
PGEN -- USA Stock  

USD 4.39  0.06  1.39%

In general, we focus on analyzing Precigen (NASDAQ:PGEN) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Precigen daily price indicators and compare them against related drivers. Let's try to outline what's happening with Precigen amid unprecedented political, and economic uncertainty.
Published over a week ago
View all stories for Precigen | View All Stories
Continue to hold Precigen (NASDAQ:PGEN)?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Precigen has an asset utilization ratio of 12.24 percent. This suggests that the company is making $0.12 for each dollar of assets. An increasing asset utilization means that Precigen is more efficient with each dollar of assets it utilizes for everyday operations. About 15.0% of the company outstanding shares are owned by corporate insiders. The book value of Precigen was at this time reported as 3.47. The company recorded a loss per share of 4.88. Precigen had not issued any dividends in recent years.
The successful prediction of Precigen stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Precigen, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Precigen based on Precigen hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Precigen's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Precigen's related companies.

Use Technical Analysis to project Precigen expected Price

Precigen technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Precigen technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Precigen trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How Precigen utilizes its cash?

To perform a cash flow analysis of Precigen, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Precigen is receiving and how much cash it distributes out in a given period. The Precigen cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Purchase by Ares Trading Sa of 6758400 shares of Precigen

Legal trades by Precigen insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Precigen insider trading alert for perchase of common stock by Ares Trading Sa, the corporate stakeholder, on 9th of October 2020. This event was filed by Precigen Inc with SEC on 2020-10-09. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for Precigen

Precigen reported the previous year's revenue of 95.56 M. Net Loss for the year was (195.85 M) with loss before overhead, payroll, taxes, and interest of (72.56 M).

Are Precigen technical ratios showing a recoup?

Latest Sortino Ratio is up to 0.09. Price may slide again. Precigen is displaying above-average volatility over the selected time horizon. Investors should scrutinize Precigen independently to ensure intended market timing strategies are aligned with expectations about Precigen volatility.

Our Final Perspective on Precigen

Whereas other entities under the biotechnology industry are still a bit expensive, Precigen may offer a potential longer-term growth to institutional investors. To conclude, as of the 11th of October 2020, we believe that at this point, Precigen is unstable with average odds of financial turmoil within the next 2 years. From a slightly different point of view, the entity appears to be overvalued. Our current 30 days 'Buy-Sell' recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Precigen. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com